Browsing ICR Divisions by title
Now showing items 1199-1218 of 4607
-
Determination of Ligand-Binding Affinity (Kd) Using Transverse Relaxation Rate (R2) in the Ligand-Observed 1H NMR Experiment and Applications to Fragment-Based Drug Discovery.
(AMER CHEMICAL SOC, 2023-08-10)High hit rates from initial ligand-observed NMR screening can make it challenging to prioritize which hits to follow up, especially in cases where there are no available crystal structures of these hits bound to the target ... -
Determining the chemical exchange saturation transfer (CEST) behavior of citrate and spermine under in vivo conditions.
(WILEY-BLACKWELL, 2016-09-01)PURPOSE: To estimate the exchange rates of labile (1) H in citrate and spermine, metabolites present in prostatic secretions, to predict the size of the citrate and spermine CEST effects in vivo. METHODS: CEST z-spectra ... -
Deterministic Evolutionary Trajectories Influence Primary Tumor Growth: TRACERx Renal.
(CELL PRESS, 2018-04-19)The evolutionary features of clear-cell renal cell carcinoma (ccRCC) have not been systematically studied to date. We analyzed 1,206 primary tumor regions from 101 patients recruited into the multi-center prospective study, ... -
Developing and testing a robotic MRI/CT fusion biopsy technique using a purpose-built interventional phantom.
(SPRINGER WIEN, 2022-11-22)BACKGROUND: Magnetic resonance imaging (MRI) can be used to target tumour components in biopsy procedures, while the ability to precisely correlate histology and MRI signal is crucial for imaging biomarker validation. ... -
Developing and Validating a Multivariable Prognostic-Predictive Classifier for Treatment Escalation of Oropharyngeal Squamous Cell Carcinoma: The PREDICTR-OPC Study.
(AMER ASSOC CANCER RESEARCH, 2024-01-17)PURPOSE: While there are several prognostic classifiers, to date, there are no validated predictive models that inform treatment selection for oropharyngeal squamous cell carcinoma (OPSCC).Our aim was to develop clinical ... -
Developing and validating a simple urethra surrogate model to facilitate dosimetric analysis to predict genitourinary toxicity.
(Elsevier BV, 2024-05-01)PURPOSE: The urethra is a critical structure in prostate radiotherapy planning; however, it is impossible to visualise on CT. We developed a surrogate urethra model (SUM) for CT-only planning workflow and tested its geometric ... -
Developing biomarker guided treatments for colorectal cancer
(Institute of Cancer Research (University Of London), 2021-09-30) -
Developing biomarker-driven treatments for oesophagogastric cancer
(Institute of Cancer Research (University Of London), 2020-08-31)Introduction Despite recent advances in both genetic characterisation and development of novel targeted agents the outlook for advanced oesophagogastric (OG) cancers remain poor and there is a need for improved biomarker-driven ... -
Developing RAS-binding antibody-derived hit compounds
(Institute of Cancer Research (University Of London), 2023-09-27) -
Development and Evaluation of Machine Learning in Whole-Body Magnetic Resonance Imaging for Detecting Metastases in Patients With Lung or Colon Cancer: A Diagnostic Test Accuracy Study.
(LIPPINCOTT WILLIAMS & WILKINS, 2023-12-01)OBJECTIVES: Whole-body magnetic resonance imaging (WB-MRI) has been demonstrated to be efficient and cost-effective for cancer staging. The study aim was to develop a machine learning (ML) algorithm to improve radiologists' ... -
Development and external validation of a dynamic prognostic nomogram for primary extremity soft tissue sarcoma survivors.
(ELSEVIER, 2019-12-01)BACKGROUND: Prognostic nomograms for patients with extremity soft tissue sarcoma (eSTS) typically predict survival or the occurrence of local recurrence or distant metastasis at time of surgery. Our aim was to develop and ... -
Development and external validation of nomograms in oropharyngeal cancer patients with known HPV-DNA status: a European Multicentre Study (OroGrams).
(SPRINGERNATURE, 2018-06-01)BACKGROUND: The proxy marker for human papillomavirus (HPV), p16, is included in the new AJCC 8th/UICC 8th staging system, but due to incongruence between p16 status and HPV infection, single biomarker evaluation could ... -
Development and responses of brain metastases during treatment with trastuzumab emtansine (T-DM1) for HER2 positive advanced breast cancer: A single institution experience.
(WILEY, 2018-05-01)Ado-trastuzumab emtansine (T-DM1) is an antibody-drug conjugate that does not cross an intact blood-brain barrier. In the EMILIA trial of T-DM1 vs capecitabine/lapatinib for HER2 positive advanced breast cancer, all patients ... -
Development and results of a patient-reported treatment experience questionnaire on a 1.5 T MR-Linac.
(ELSEVIER IRELAND LTD, 2021-09-01)INTRODUCTION: With the implementation of new radiotherapy technology, it is imperative that patient experience is investigated alongside efficacy and outcomes. This paper presents the development of a specifically designed ... -
Development and validation for research assessment of Oncotype DX® Breast Recurrence Score, EndoPredict® and Prosigna®.
(NATURE RESEARCH, 2021-02-12)Multi-gene prognostic signatures including the Oncotype® DX Recurrence Score (RS), EndoPredict® (EP) and Prosigna® (Risk Of Recurrence, ROR) are widely used to predict the likelihood of distant recurrence in patients with ... -
Development and validation of a follow-up methodology for a randomised controlled trial, utilising routine clinical data as an alternative to traditional designs: a pilot study to assess the feasibility of use for the BladderPath trial.
(BMC, 2020-10-31)BACKGROUND: Bladder cancer outcomes have not changed significantly in 30 years; the BladderPath trial (Image Directed Redesign of Bladder Cancer Treatment Pathway, ISRCTN35296862) proposes to evaluate a modified pathway ... -
Development and validation of a LC-MS/MS method for the quantification of the checkpoint kinase 1 inhibitor SRA737 in human plasma.
(FUTURE SCI LTD, 2017-07-01)AIM: SRA737 is an orally active small-molecule inhibitor of checkpoint kinase 1 being investigated in an oncology setting. A HPLC-MS/MS method for quantifying plasma concentrations of SRA737 was validated. METHODS & RESULTS: ... -
Development and Validation of a New BAG-1L-Specific Antibody to Quantify BAG-1L Protein Expression in Advanced Prostate Cancer.
(ELSEVIER SCIENCE INC, 2023-08-29)BCL-2-associated athanogene-1L (BAG-1L) is a critical co-regulator that binds to and enhances the transactivation function of the androgen receptor, leading to prostate cancer development and progression. Studies investigating ... -
Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE).
(AMER ASSOC CANCER RESEARCH, 2020-10-15)PURPOSE: Gene expression-based molecular subtypes of high-grade serous tubo-ovarian cancer (HGSOC), demonstrated across multiple studies, may provide improved stratification for molecularly targeted trials. However, ...